Date Filed | Type | Description |
08/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/18/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
08/10/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/10/2023 |
8-K
| Investor presentation, Quarterly results |
07/27/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
06/09/2023 |
4
| HELTON SANDRA L (Director) has filed a Form 4 on OptiNose, Inc.
Txns:
| Granted 53,500 options to buy
@ $1.18, valued at
$63.1k
|
|
06/09/2023 |
4
| Bednarski Eric (Director) has filed a Form 4 on OptiNose, Inc.
Txns:
| Granted 53,500 options to buy
@ $1.18, valued at
$63.1k
|
|
06/09/2023 |
4
| Dempsey Kyle (Director) has filed a Form 4 on OptiNose, Inc.
Txns:
| Granted 53,500 options to buy
@ $1.18, valued at
$63.1k
|
|
06/09/2023 |
4
| FLETCHER R JOHN (Director) has filed a Form 4 on OptiNose, Inc.
Txns:
| Granted 53,500 options to buy
@ $1.18, valued at
$63.1k
|
|
06/09/2023 |
4
| GROENHUYSEN WILHELMUS CM (Director) has filed a Form 4 on OptiNose, Inc.
Txns:
| Granted 53,500 options to buy
@ $1.18, valued at
$63.1k
|
|
06/09/2023 |
4
| Heyman Tomas J. (Director) has filed a Form 4 on OptiNose, Inc.
Txns:
| Granted 53,500 options to buy
@ $1.18, valued at
$63.1k
|
|
06/09/2023 |
4
| Owen Catherine E. (Director) has filed a Form 4 on OptiNose, Inc.
Txns:
| Granted 53,500 options to buy
@ $1.18, valued at
$63.1k
|
|
05/16/2023 |
4
| Avista Capital Partners II GP, LLC (10% Owner) has filed a Form 4 on OptiNose, Inc.
Txns:
| Disposed of 10,102,707 shares
@ $0 Disposed of 3,328,648 shares
@ $0 Disposed of 807,995 shares
@ $0 Acquired 48,370 shares
@ $0 |
|
05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/11/2023 |
8-K
| Investor presentation, Quarterly results |
05/04/2023 |
8-K
| Quarterly results |
05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/21/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
04/17/2023 |
8-K
| Quarterly results |
03/28/2023 |
8-K
| Quarterly results |
03/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/07/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
03/07/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/07/2023 |
8-K
| Investor presentation, Quarterly results |
02/14/2023 |
SC 13G/A
| GREAT POINT PARTNERS LLC reports a 10% stake in OPTINOSE, INC. |
02/14/2023 |
SC 13D/A
| MVM Partners, LLC reports a 14.9% stake in OPTINOSE, INC. |
02/09/2023 |
SC 13G/A
| FMR LLC reports a 13.3% stake in OPTINOSE INC |
02/02/2023 |
4
| Mahmoud Ramy A (CEO) has filed a Form 4 on OptiNose, Inc.
Txns:
| Granted 336,135 shares
@ $0 Granted 549,202 options to buy
@ $1.74, valued at
$955.6k
|
|
01/31/2023 |
8-K
| Appointed a new director |
01/19/2023 |
SC 13G/A
| KRUTTSCHNITT THEODORE H III has filed a Schedule 13D for OptiNose, Inc. |
01/17/2023 |
4
| Marino Michael F III (Chief Legal Officer & Corp Sec) has filed a Form 4 on OptiNose, Inc.
Txns:
| Sold 5,241 shares
@ $1.77, valued at
$9.3k
|
|
01/17/2023 |
4
| Mahmoud Ramy A (President and COO) has filed a Form 4 on OptiNose, Inc.
Txns:
| Sold 8,148 shares
@ $0 |
|
|